Rhenman & Partners Asset Management AB
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1599882
Stockholm, V7
Position in SYRE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$10,591,454
New position
Shares Held
119,300
first reported quarter
Ownership
0.135%
of shares outstanding
% of Portfolio
1.00%
of 13F equity value
Holder Rank
#71
of 266 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rhenman & Partners Asset Management AB holds $335,352,902 across 39 Biotechnology names. SYRE ranks #13 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
87,440 | $21,070,416 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
27,390 | $17,078,760 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
290,500 | $16,622,410 | |
| 4 | NRIX |
Nurix Therapeutics, Inc.
|
684,250 | $16,599,905 | |
| 5 | MIRM |
Mirum Pharmaceuticals, Inc.
|
139,205 | $16,296,729 | |
| 6 | INSM |
INSMED Inc
|
151,960 | $16,201,975 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
63,050 | $15,432,748 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,685 | $15,242,160 |
All Filings in SYRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,591,454 | 119,300 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||